The stock's market-beating momentum has come crashing to a halt, following shocking allegations from one of the world's largest pharmaceutical companies.Up-and-coming telehealth company Hims & Hers Health (HIMS 11.76%) has capitalized on the weight loss drug craze to become one of the market's top performers over the past few years.However, recently, pharmaceutical giant Novo Nordisk, the maker of popular GLP-1 agonist weight loss drug Wegovy, terminated its sales partnership with the company due to its con ...